- $288.68bn
- $313.21bn
- $54.07bn
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains
Live Markets: Trail mix: Jobless claims, home sales, consumer credit
Live Markets: US stocks gain early with boost from financials, tech
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags
Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial
Live Markets: STOXX bounces back, AstraZeneca drags
AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial
UK Stocks-Factors to watch on July 9 (updated)
Brief: AstraZeneca's Wainua Misses Phase III Primary Endpoint In Cardio-Ttransform Trial
AstraZeneca's Wainua fails key heart disease trial, shares tumble (updated)
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
Update on CARDIO-TTRansform Phase III trial
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports (updated)
Brief: AstraZeneca Spokesperson Says Co in Discussions With NHS, NICE To Support Access To Enhertu
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
Brief: Astrazeneca, Daiichi Near UK Price Deal For Breast Cancer Drug-Bloomberg News